2016 perfectly highlighted the strengths of the Ergomed business: the visibility of its Contracted Revenues and the potential upside from co-development deals. Contracted revenues now stand at an impressive £70m, up from £42m and the outlook remains auspicious. FY2016 came in ahead of revised forecasts and there are upgrades to FY2017 onwards. Meanwhile, Haemostatix is moving into the next phase of clinical trials, and the co-development programmes continue to progress. Our valuat
11 Apr 2017
£70m contracted revenues still to come
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
£70m contracted revenues still to come
- Published:
11 Apr 2017 -
Author:
Elizabeth Klein -
Pages:
6
2016 perfectly highlighted the strengths of the Ergomed business: the visibility of its Contracted Revenues and the potential upside from co-development deals. Contracted revenues now stand at an impressive £70m, up from £42m and the outlook remains auspicious. FY2016 came in ahead of revised forecasts and there are upgrades to FY2017 onwards. Meanwhile, Haemostatix is moving into the next phase of clinical trials, and the co-development programmes continue to progress. Our valuat